公司点评报告 · 医药行业 业绩稳健增长，制剂&原料药释放新增长潜能 —— 2024 年中报业绩点评 2024 年 8 月 27 日 | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------| | ⚫ ...

中国银河证券|CGS 乘新能源之势，塑海外产业集群 ─中资出海专题系列研究（新能源汽车产业链） 汽车首席分析师：石金漫 研究助理：秦智坤 乘新能源之势,塑海外产业集群 -中资出海专题系列研究(新能源汽车产业链) 核心观点 ● 新能源:加速出海,塑造本地化形象:1)车型结构中,现阶段纯电动乘用车 出口占新能源乘用车出口比重的 80%,参考全球龙头丰田汽车,具备经济性与 便捷性的 PHEV 有望替代燃油车,成长空间更大;2)出口市场中,综合考虑经 济增长水平、电动汽车政策、汽车市场消费规模、汽车企业竞争格局、车型周期 等各项因素,欧洲、北美、东南亚已经成为我国新能源乘用车出口的最具潜力市 场;3)产业升级趋势显著,新能源乘用车出口均价显著高于燃油车,发达国家 广泛认可,产能出海将有效拉动企业利润率;4)合作模式中,产能出口兴起, 全球型主机厂海外产能普遍高于本国,产能出海是自主品牌走向全球的必由之 路,也最大限度的适应本地化及规避风险。此外,部分主机厂创新技术输出模式 进入欧洲市场,有望助力技术实力领先的自主品牌获得额外收入,摊薄技术开发 成本,走向"技术驱动"的新盈利模式。新合作模式下,将转由中方主导产品定 义 ...

工业企业盈利平稳,新旧动能利润分化 -2024 年 7 月工业企业利润分析 8 月 27 日国家统计局发布: 1–7 月份,全国规模以上工业企业实现营业收 入 75.93 万亿元,同比增长 2.9%;利润总额 40.99万亿元,累计同比增长 3.6%(前值3.5%）。7月当月利润同比增长 4.1%(前值 3.6%)。 利润率回升是工业企业利润回升的主要原因。从量、价、利润率三要素来看, 7 月工业生产继续边际小幅收缩,规模以上工业增加值增速7月录得5.1%(前 值 5.3%);PPI降幅与前值持平(-0.8%);7月营业收入利润率为5.40%, 虽然环比下降0.1pct,但同比上升 0.19%(去年同期 5.39%),因此利润率 同比上行是工业企业利润同比增速边际回升的主要原因。 ● 成本端压力下降提升企业利润。7月份企业利润率同比上行的主要原因是成 本端的压力继续缓解。7月 CRB指数同比下降 3.58%,PMI方面可以也看出, 7月原材料购进价格较前值51.7%下降至49.9%,掉入收缩区间。每百元营业 收入中的费用环比下降至 8.41元（前值 8.43元）。 ● 出口增速虽有所回落但继续拉动工业企业生产 ...

中国银河证券|CGS 大浪淘沙, 乘势而起 ——中企出海专题系列研究（化工篇） 化工分析师：翟启迪、孙思源 大浪淘沙,乘势而起 —中企出海专题系列研究(化工篇) 核心观点 ● 全球化工行业增速放缓,中国企业逆流而上。化工行业是国民经济基础性、 支柱型产业,是推动工业稳定增长、经济平稳运行的关键环节。我国现已成为 全球最大的化工市场,且近年来我国化工品出口额及在全球所占份额稳步提 升。2022年我国化工品出口额 3132亿美元,同比增长 18.6%、占全球化工品 出口总额的 10.2%。在全球化工品需求增速放缓,部分海外大型企业相继关停 落后、高成本产能的趋势下,我国化工品产量增速仍具备较强韧性。中长期来 看,中国有望成为驱动全球化工行业增长的主力。 ● 挑战与机遇并存,看好化工出海相关投资机会。在全球市场竞争加剧、地缘 冲突和贸易摩擦频发等背景下,尽管我国化工行业出海面临诸多挑战,全球化 工行业大浪淘沙,中国化工企业有望借助出海乘势而起,看好相关领域投资机 会。一是,出海探寻战略资源品,确保产业链上下游供应链安全。二是,全球 市场竞争力逐步提升,产品出海缓和国内供应压力。三是,打破发展壁垒,产 能出海谋求发展 ...

*能置换暂停,供给侧有望迎来结构性改革 2024 年 08月 25 日 一周钢铁板块指数下跌。本周上证指数跌幅为 1.06%;深证成指跌幅为 2.25%;创业板指数跌幅为 2.82%;一级行业指数中,钢铁板块跌幅为 2.91%。 根据我们对于钢铁行业公司划分子板块数据,板材、特钢跌幅较小,分别为 2.79%、3.10%。钢铁板块个股中,上涨和下跌的个股占比分别为 6.67%和 93.33%。 ● 工信部暂停钢铁产能置换工作,钢铁供给侧有望迎来结构性改革。8月20 日,工信部发表《工业和信息化部办公厅关于暂停钢铁产能置换工作的通知》, 对钢铁产能置换办法进行修订,进一步深化钢铁行业供给侧结构性改革,完善 钢铁行业产能置换政策。《钢铁行业产能置换实施办法》实施以来,钢铁行业 通过钢铁产能置换,有力促进了行业改造升级、结构调整、布局优化和兼并垂 组,但仍存在政策执行不到位、监督落实机制不完善、与行业发展形势和需求 不相适应等问题。当前,钢铁行业供需关系面临新挑战,绿色低碳、结构调整、 布局优化、兼并重组等对产能置换政策提出了新要求。工信部规定各地区自 2024年8月23日起,暂停公示、公告新的钢铁产能置换方案。未按 ...

Investment Rating - The report maintains a "Recommend" rating for Li Auto (2015 HK) [3] Core Views - Li Auto has emerged as the leading domestic new energy vehicle (NEV) manufacturer, with strong brand and product definition capabilities, positioning itself as a leader in the family luxury segment [1] - The company's dual-energy strategy (extended-range and pure electric) is expected to drive long-term growth, despite short-term financial pressures due to increased R&D and channel expansion costs [1] - Li Auto's organizational restructuring, particularly the transition to a matrix structure 2 0, is expected to enhance operational efficiency and support future growth [1] Financial Performance and Projections - In 2024 Q1, Li Auto's net profit declined by 36% YoY to RMB 600 million, but profitability is expected to recover from Q2 onwards due to cost reductions from economies of scale [1] - Revenue is projected to grow from RMB 151 28 billion in 2024 to RMB 289 41 billion in 2026, with net profit increasing from RMB 7 74 billion to RMB 22 54 billion over the same period [1][2] - EPS is forecasted to rise from RMB 3 65 in 2024 to RMB 10 62 in 2026 [2] Product Strategy - Li Auto's L-series extended-range vehicles, covering the RMB 250,000-450,000 price range, have achieved strong sales, with the L6 model driving significant growth in 2024 [1][23] - The company's pure electric strategy is supported by accelerated supercharging station deployment, with 700 stations built by July 2024, laying the foundation for future high-end pure electric models [1][61] - Li Auto plans to launch five high-voltage pure electric models by 2025, targeting the RMB 200,000+ market segment [59] Market Position and Competitive Advantage - Li Auto ranked 5th in NEV brand sales in 2023, with a 182 21% YoY growth in sales, solidifying its position as a top player in the domestic NEV market [10] - The company's unique product positioning, combining extended-range technology, large SUVs, and advanced smart features, has driven its success in the family luxury segment [26][27] - Li Auto's intelligent driving capabilities, including the rollout of no-map NOA (Navigate on Autopilot), have positioned it as a leader in smart driving technology [50][51] Organizational Structure and Management - Li Auto's organizational evolution, from a vertical to a matrix structure, has been a key driver of its growth, with founder Li Xiang focusing on product and strategy in the latest 2 0 iteration [17][21] - The company's centralized equity structure, with Li Xiang holding 69 2% of voting rights, enables efficient decision-making and strategic adjustments [17] Future Outlook - Li Auto is expected to sell 535,000 vehicles in 2024, with pure electric SUVs contributing significantly to sales from 2025 onwards [63] - The company aims to lead the high-end pure electric market by leveraging its advanced charging infrastructure and product innovation [61][62]

公司点评报告 · 农林牧渔行业 H1 出口向好&品牌快增,业绩扭亏为盈 核心观点 2024年8月26日 | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Recommended" rating for the company [3][4]. Core Views - The company reported a revenue of 6.218 billion yuan for the first half of 2024, a decrease of 9.12% year-on-year, and a net profit attributable to shareholders of 72 million yuan, down 84.17% [2]. - The core business performance is expected to stabilize in the second half of the year, despite short-term fluctuations due to industry restructuring and competition [2]. - The company has been enhancing operational efficiency through digitalization and AI-driven processes, which is expected to improve service delivery [2]. Summary by Sections Financial Performance - For H1 2024, the company experienced a decline in diagnostic services and products, with revenues of 2.362 billion yuan from diagnostic services (down 13.40%) and 4.085 billion yuan from diagnostic products (down 5.94%) [2]. - The company incurred credit impairment losses of 255 million yuan, significantly impacting apparent profits, primarily due to extended aging of accounts receivable [2]. - The revenue structure shows that the ICL segment grew by 6.32% year-on-year, while the special inspection business generated 961 million yuan, accounting for 40.69% of the diagnostic services revenue [2]. Future Outlook - The company anticipates a significant improvement in apparent growth rates in the second half of 2024, driven by a lower base effect and recovery in hospital testing volumes [3]. - The net profit forecasts for 2024-2026 are adjusted to 587 million, 726 million, and 883 million yuan, representing year-on-year growth rates of 90.87%, 23.76%, and 21.62% respectively [3][8]. - The expected earnings per share (EPS) for the same period are projected to be 0.94, 1.16, and 1.41 yuan, with corresponding price-to-earnings (PE) ratios of 11, 9, and 7 times [3][8].

行业月报· 农林牧渔行业 8 月生猪头均利润超 600 元，行业景气高企 8 月行业动态报告 2024年8月 26 日 核心观点 ● ● 7 月 CPI 同比+0.5%,猪肉价格持续上涨。7月我国 CPI 同比+0.5%,连续 6 个月同比转正,其中食品项同比持平,食品中猪肉同比+20.4%;CPI 环比 +0.5%,其中食品项环比+1.2%,食品中猪肉环比+2%。7月农产品进口金额 177.65 亿美元(-5.2%),出口金额 82.54 亿美元(+1.6%),贸易逆差 95.12 亿美元(同比-10%）。 8 月猪价突破 20元/kg,头均利润突破 600元。根据博亚和讯,8月猪价 小幅上行,8月23日为20.03元/kg,较7月末上涨1.9%;8月23日自繁自 养、外购仔猪养殖分别盈利 641.09元/头、435.39元/头。7月末我国能繁母 猪存栏量 4041万头,环比仅+0.07%,同比-5.4%。我们认为 24年生猪年度 均价同比上行,且H2价格优于 H1 确定性高。此外我们考虑行业养殖成本相 对低位且具备下行潜力,行业盈利弹性有望超预期。建议关注成本控制行业领 先/持续向好、资金面相对健康、估值 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4][6]. Core Views - The company's performance in the first half of 2024 showed a significant decline in revenue and net profit due to fluctuations in demand, with total revenue of 4.308 billion yuan (-13.50%) and net profit of 1.120 billion yuan (-25.02%) [1][2]. - The company is a leader in home medical devices, focusing on three core areas: respiratory and oxygen therapy, diabetes care, and infection control, with a continuous improvement in product structure and brand advantages [3][4]. Summary by Sections Financial Performance - For the first half of 2024, the company reported a revenue of 4.308 billion yuan, a decrease of 13.50%, and a net profit of 1.120 billion yuan, down 25.02%. The operating cash flow also decreased by 32.42% to 1.013 billion yuan [1][2]. - In Q2 2024, revenue was 2.076 billion yuan (-8.82%), with a net profit of 461 million yuan (-40.96%) [1]. Business Segments - Respiratory treatment revenue was 1.642 billion yuan (-28.88%), accounting for 38.11% of total revenue, with a gross margin of 52.11% [2]. - Diabetes care revenue increased by 54.94% to 562 million yuan, representing 13.05% of total revenue, with a gross margin of 60.19% [2]. - Infection control revenue decreased by 26.79% to 311 million yuan, accounting for 7.21% of total revenue [2]. - Home electronic testing and in vitro diagnostics generated 935 million yuan (-12.49%) in revenue, while emergency revenue increased by 34.66% to 108 million yuan [2]. Profitability and Shareholder Returns - The overall gross margin for H1 2024 was 50.06%, a decrease of 1.43 percentage points, but Q2 saw a slight improvement to 50.19% [3]. - The company announced its first interim dividend, proposing a cash dividend of 4 yuan per 10 shares, reflecting a commitment to shareholder returns [3]. Future Outlook - The company expects to see continued growth in overseas markets as product registrations and local team developments progress [2]. - The forecast for net profit for 2024-2026 is adjusted to 2.210 billion yuan, 2.542 billion yuan, and 2.921 billion yuan, reflecting a year-on-year decrease of 7.75% in 2024, followed by growth in subsequent years [3][6].